Market Exclusive

Analyst Activity – HC Wainwright Initiates Coverage On Celldex Therapeutics (NASDAQ:CLDX) With a Buy

Analyst Ratings For Celldex Therapeutics (NASDAQ:CLDX)

Today, HC Wainwright initiated coverage on Celldex Therapeutics (NASDAQ:CLDX) with a Buy with a price target of $10.00.

There are 2 hold ratings, 6 buy ratings on the stock.

The current consensus rating on Celldex Therapeutics (NASDAQ:CLDX) is Buy (Score: 2.75) with a consensus target price of $8.08 per share, a potential 252.98% upside.

Some recent analyst ratings include

Recent Insider Trading Activity For Celldex Therapeutics (NASDAQ:CLDX)
Celldex Therapeutics (NASDAQ:CLDX) has insider ownership of 4.10% and institutional ownership of 65.85%.

Recent Trading Activity for Celldex Therapeutics (NASDAQ:CLDX)
Shares of Celldex Therapeutics closed the previous trading session at 2.29 down -0.01 -0.43% with 931,317 shares trading hands.

Exit mobile version